Teladoc price target lowered to $14 from $16 at Jefferies Jefferies analyst Glen Santangelo lowered the firm's price target on Teladoc to $14 from $16 and keeps a Hold rating on the shares after updating the firm's model to reflect Q1 results and updated management commentary. The firm is moderating its outlook for the BetterHelp business given year-over-year comps that "continue to trend in the wrong direction," the analyst tells investors.